JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Strona główna・Stock List・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Closed

SectorHealthcare

21.52 -0.6

Buy Sell

Overview

Share price change

24h

Current

Min

21.43

Max

21.64

Key metrics
By Trading Economics
Income	-14M -50M
Sales	12M 128M
Profit margin	-39.506
Employees	1,784
EBITDA	-17M -48M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+63.74% upside

Dividends
By Dow Jones
Next Earnings	7 maj 2026

Market Stats
By TradingEconomics
Market Cap	261M 2.5B
Previous open	22.12
Previous close	21.52

News Sentiment

By Acuity

43%

57%

135 / 347 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

28.13 / 31.12 Support & Resistance

Zai Lab Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

1 maj 2026, 21:36 UTC

Acquisitions, Mergers, Takeovers

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

1 maj 2026, 20:40 UTC

Acquisitions, Mergers, Takeovers

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

1 maj 2026, 18:37 UTC

Major Market Movers

Senseonic Shares Slide on Underwritten Offering Price

1 maj 2026, 16:46 UTC

Major Market Movers

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

2 maj 2026, 19:57 UTC

Acquisitions, Mergers, Takeovers

Berkshire CEO Greg Abel Takes the Stage, Making a Case for the Post-Buffett Era -- 3rd Update

2 maj 2026, 15:24 UTC

Earnings

Berkshire CEO Greg Abel Takes the Stage, Talks Through Quarterly Results -- Update

2 maj 2026, 12:46 UTC

Earnings

Acquisitions, Mergers, Takeovers

Berkshire Profits More Than Double on Gains in Insurance, Railroad, Energy Businesses -- WSJ

2 maj 2026, 08:20 UTC

Market Talk

Financial Services Roundup: Market Talk

1 maj 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

1 maj 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1 maj 2026, 20:42 UTC

Earnings

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

1 maj 2026, 19:33 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 maj 2026, 19:33 UTC

Market Talk

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

1 maj 2026, 19:18 UTC

Market Talk

Major News Events

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

1 maj 2026, 19:13 UTC

Market Talk

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

1 maj 2026, 18:36 UTC

Earnings

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

1 maj 2026, 18:35 UTC

Earnings

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1 maj 2026, 18:28 UTC

Earnings

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

1 maj 2026, 18:27 UTC

Market Talk

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

1 maj 2026, 18:14 UTC

Acquisitions, Mergers, Takeovers

Barclays Completes Acquisition of Best Egg

1 maj 2026, 18:04 UTC

Earnings

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

1 maj 2026, 17:43 UTC

Market Talk

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

1 maj 2026, 17:37 UTC

Market Talk

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

1 maj 2026, 17:30 UTC

Market Talk

Earnings

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

1 maj 2026, 17:28 UTC

Market Talk

Earnings

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

1 maj 2026, 17:21 UTC

Market Talk

Earnings

Apple Seen Absorbing Higher Memory Costs -- Market Talk

1 maj 2026, 17:19 UTC

Market Talk

Major News Events

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

1 maj 2026, 16:38 UTC

Market Talk

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

1 maj 2026, 16:23 UTC

Acquisitions, Mergers, Takeovers

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

1 maj 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

Peer Comparison

Price change

Zai Lab Ltd ADR Forecast

Price Target

By TipRanks

63.74% upside

12 Months Forecast

Average 35.27 USD 63.74%

High 47 USD

Low 21.8 USD

Based on 4 Wall Street analysts offering 12 month price targets forZai Lab Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Zai Lab Ltd ADR - Dist in the past 3 months.

Technical Score

By Trading Central

28.13 / 31.12Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

135 / 347 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.